文献速递慢性肾脏病

痛风合并慢性肾脏病的争议与实践管理

Controversies and practical management of patients with gout and chronic kidney disease.
PubMed 文献 · Kidney Int · 2024-07-20

高尿酸血症是慢性肾脏病进展中潴留的毒素,可导致痛风和系统性炎症,增加心血管死亡风险;多达三分之一的慢性肾脏病患者有痛风史,但不足25%的患者血尿酸有效降至≤6 mg/dl。管理复杂、药物禁忌和剂量调整等因素导致许多肾科医生不主导痛风管理,作者主张肾科医生应积极管理并采用多学科团队方法。

要点

  • 慢性肾脏病患者痛风患病率高,但血尿酸达标率低。
  • 肾科医生应主动管理痛风,而非仅交由初级医生或风湿科医生。
  • 推荐肾科与风湿科团队协作管理痛风。

核心结论

  • 肾科医生应将痛风视为慢性肾脏病的重要并发症并积极管理。
  • 推荐采用包括肾科医生在内的团队方法管理痛风。

主要发现

  • 多达三分之一的慢性肾脏病患者有痛风史。
  • 不足25%的痛风合并慢性肾脏病患者血尿酸有效降至≤6 mg/dl。
  • 高尿酸血症的临床表现包括痛风和系统性炎症,与心血管死亡风险增加相关。

临床怎么用

  • 肾科医生应积极参与痛风管理,注意药物禁忌和剂量调整。
  • 采用肾科与风湿科协作的团队模式管理痛风。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uric acid is a toxin retained with advancing kidney disease. Clinical manifestations of hyperuricemia include gout and systemic inflammation that are associated with increased risk of cardiovascular mortality. As many as one-third of all patients with chronic kidney disease have a history of gout, yet <25% of these patients are effectively treated to target serum urate levels of ≤6 mg/dl. A major reason for ineffective management of gout and hyperuricemia is the complexity in managing these patients, with some medications contraindicated and others requiring special dosing, potential drug interactions, and other factors. Consequently, many nephrologists do not primarily manage gout despite it being a common complication of chronic kidney disease, leaving management to the primary physician or rheumatologist. We believe that kidney specialists should consider gout as a major complication of chronic kidney disease and actively manage it in their patients. Here, we present insights from nephrologists and rheumatologists for a team approach to gout management that includes the nephrologist.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Johnson RJ, Mandell BF, Schlesinger N, et al. Controversies and practical management of patients with gout and chronic kidney disease. Kidney Int. 2024. PMID: 39033815. doi:10.1016/j.kint.2024.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。